Cambridge Healthtech Institute’s 4th Annual

Blood-Brain Barrier and CNS Drug Discovery
( 血脑障壁和中枢神经系统治疗药物的新药发现 )

Strategies and Tools to Address Hurdles in CNS Drug Discovery

2019年4月12日

 

The blood-brain barrier (BBB) plays a critical role in brain homeostasis – a function it does so well that scientists and drug developers continue to grapple with the challenges of delivering drugs into the brain to treat devastating and life-threatening diseases such as brain cancer and neurodegenerative disorders. As we understand more about the state of the BBB in a healthy and a disease-challenged brain, novel strategies, methods and tools are developed to design and study brain-penetrant molecules. Cambridge Healthtech Institute’s 4th Annual Blood-Brain Barrier and CNS Drug Discovery symposium will once again bring together drug discovery experts to discuss advances in the CNS drug discovery, including the progress towards designing brain-penetrant molecules and emerging drug delivery approaches.

Coverage will include, but is not limited to:

  • Case studies on the discovery of novel, potent and selective inhibitors for the treatment of neurodegenerative disorders and brain cancers
  • Discovery and development of anti-cancer inhibitors targeting tyrosine kinases, PI3Ks, BRAF, MEK, CDK4/6 and HDACs
  • Discovery and development of CNS-focused inhibitors targeting DLK and LRRK2  
  • Macrocyclic inhibitors crossing the BBB 
  • Intact BBB vs. disease-altered BBB
  • Latest developments in CNS drug discovery

* 活动内容有可能不事先告知作更动及调整。